2020年8月23日

更多的人才冲到合成生物学金矿:风险资本家叶子罗氏米切尔•穆茨加入密码子资本8月19日,2020年合成生物学出售4万亿美元bioeconomy锄头和铁锹,和密码子资本看到了这个机会。其投资的合成生物学,包括积极进取的独角兽主生物,Zymergen,螺栓线程,等等。现在,密码子的资本和其创始人卡尔待价而沽,吸引新的人才。米切尔Mutz-the完成风险投资者,生物技术的企业家,发明家已离开罗氏公司风险资本基金加入密码子在其总部位于旧金山的办公室。如果你遵循我的专栏,你知道合成生物学是一个快速增长的领域的前沿制造。它结合了计算、自动化和读/写/编辑DNA的能力使可持续发展,高性能的产品,生物学。这包括更好的药品和诊断Covid-19、智能药物对癌症和糖尿病,与生物技术和产品我们不喜欢汽车,运动服装,和手机。加入了密码子米切尔•穆茨的资本去追求一个简单的投资理论:伟大的技术团队,把不可能变为可能。Mutz有第一手经验在这个行业。在Labcyte他是第一个员工,公司为科研开发革命性的实验室设备,两年前退出了一个令人印象深刻的贝克曼库尔特以3.1亿美元的价格出售。 In addition to being Labcyte’s first employee, Mutz also founded Amplyx Pharmaceuticals in 2007, a small molecule therapeutics company that has raised over $140 million in venture financing and recently completed a phase two clinical trial. After three and a half years as senior investment director at Roche Ventures, he’s joining the Codon Capital team , focusing on therapeutics and synthetic biology. With a Ph.D. in chemistry from the University of Rochester, experience working in midsize biotech companies, and 36 issued patents, Mutz sees himself as an investor, serial entrepreneur, and inventor. His expertise and long-time connection to Handelsman make him excited about his new role at Codon Capital. “I’m a huge synthetic biology fan. I’ve been thrilled beyond belief, although we didn’t envision at the time how much Labcyte has become involved with being an engine for synthetic biology,” says Mutz. “I’m very excited to be more active in that space.” Although the economic outlook is a little more uncertain now, Handelsman sees no need to put his foot on the brake. Karl Handelsman, founder of Codon Capital and synthetic biology investor, at SynBioBeta. “Even though it is a time of turmoil, the need for early-stage innovation has never been greater,” says Handelsman. “This is a time when entrepreneurs and investors are stepping up to do even bolder things. It’s a tough time, but it’s a very good time to start things. We need more innovation, and entrepreneurs have a robust desire to build out really important companies.” What does Codon Capital look for in biotech companies? In a challenging technical and economic landscape, Handelsman says Codon Capital’s investment thesis is simple: “We back great technical teams to make the impossible possible.” Mutz and Handelsman are not the only ones who see this young industry’s potential: synthetic biology investment has topped $18 billion over the last ten years . Whether it’s improving humans’ lives, sustaining the planet, or capitalizing on the coming bio-industrial revolution, more and more investors see synthetic biology as the ultimate enabling technology of the triple bottom line . Originally published on Forbes: https://www.forbes.com/sites/johncumbers/2020/08/18/more-talent-rushes-to-the-synthetic-biology-gold-mine-venture-capitalist-mitchell-mutz-leaves-roche-to-join-codon-capital/